{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:13:18Z","timestamp":1774966398735,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006245","name":"Ministry of Science and Technology, Israel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40262-026-01625-5","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:20:08Z","timestamp":1771057208000},"page":"609-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8199-3080","authenticated-orcid":false,"given":"Rachel","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0177-2069","authenticated-orcid":false,"given":"Khaled","family":"Sandouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-1806","authenticated-orcid":false,"given":"Lana","family":"Zighan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4984-7689","authenticated-orcid":false,"given":"Shaul","family":"Ya\u2019ari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-4171","authenticated-orcid":false,"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-1379","authenticated-orcid":false,"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"1625_CR1","volume-title":"Harrison\u2019s principles of internal medicine","author":"JL Jameson","year":"2022","unstructured":"Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison\u2019s principles of internal medicine. 21st ed. New York: McGraw-Hill Education; 2022.","edition":"21"},{"key":"1625_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","volume":"151","author":"BT Samuelson","year":"2017","unstructured":"Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest. 2017;151:127\u201338. https:\/\/doi.org\/10.1016\/j.chest.2016.08.1462.","journal-title":"Chest"},{"key":"1625_CR3","unstructured":"DailyMed. SAVAYSA: edoxaban tosylate tablet, film coated. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66. Accessed 17 Jun 2025."},{"key":"1625_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","volume":"30","author":"E Perzborn","year":"2010","unstructured":"Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30:376\u201381. https:\/\/doi.org\/10.1161\/ATVBAHA.110.202978.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1625_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/NYAS.12136","volume":"1291","author":"TC Sarich","year":"2013","unstructured":"Sarich TC, Peters G, Berkowitz SD, Misselwitz F, Nessel CC, Burton P, et al. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci. 2013;1291:42\u201355. https:\/\/doi.org\/10.1111\/NYAS.12136.","journal-title":"Ann N Y Acad Sci"},{"key":"1625_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1\u201316. https:\/\/doi.org\/10.1007\/S40262-013-0100-7.","journal-title":"Clin Pharmacokinet"},{"key":"1625_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40256-019-00329-5","volume":"19","author":"TL Knotts","year":"2019","unstructured":"Knotts TL, Mousa SA. Anticoagulation in venous thromboembolism prophylaxis in medically ill patients: potential impact of NOACs. Am J Cardiovasc Drugs. 2019;19:365\u201376. https:\/\/doi.org\/10.1007\/s40256-019-00329-5.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1625_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.987652","volume":"9","author":"J Lai","year":"2022","unstructured":"Lai J, Feng S, Xu S, Liu X. Effects of oral anticoagulant therapy in patients with pulmonary diseases. Front Cardiovasc Med. 2022;9:987652. https:\/\/doi.org\/10.3389\/fcvm.2022.987652.","journal-title":"Front Cardiovasc Med"},{"key":"1625_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1160\/TH10-06-0393","volume":"105","author":"YC Barrett","year":"2011","unstructured":"Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost. 2011;105:181\u20139. https:\/\/doi.org\/10.1160\/TH10-06-0393.","journal-title":"Thromb Haemost"},{"key":"1625_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cnc.2018.11.005","volume":"31","author":"M Young","year":"2019","unstructured":"Young M. Atrial fibrillation. Crit Care Nurs Clin North Am. 2019;31:77\u201390. https:\/\/doi.org\/10.1016\/j.cnc.2018.11.005.","journal-title":"Crit Care Nurs Clin North Am"},{"key":"1625_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1055\/s-0039-1679906","volume":"119","author":"J Weitz","year":"2019","unstructured":"Weitz J, Chan N. Long-term management of venous thromboembolism: lessons from EINSTEIN CHOICE and other extension trials. Thromb Haemost. 2019;119:689\u201394. https:\/\/doi.org\/10.1055\/s-0039-1679906.","journal-title":"Thromb Haemost"},{"key":"1625_CR12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/STROKEAHA.119.025536","volume":"50","author":"S-R Lee","year":"2019","unstructured":"Lee S-R, Choi E-K, Kwon S, Han K-D, Jung J-H, Cha M-J, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019;50:2245\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025536.","journal-title":"Stroke"},{"key":"1625_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005894","volume":"13","author":"S-R Lee","year":"2020","unstructured":"Lee S-R, Choi E-K, Kwon S, Jung J-H, Han K-D, Cha M-J, et al. Effectiveness and safety of direct oral anticoagulants in relation to temporal changes in their use. Circ Cardiovasc Qual Outcomes. 2020;13:e005894. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.005894.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1625_CR14","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1161\/STROKEAHA.118.021990","volume":"49","author":"T Forslund","year":"2018","unstructured":"Forslund T, Komen JJ, Andersen M, Wettermark B, von Euler M, Mantel-Teeuwisse AK, et al. Improved stroke prevention in atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants. Stroke. 2018;49:2122\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.118.021990.","journal-title":"Stroke"},{"key":"1625_CR15","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/eurheartj\/ehy411","volume":"39","author":"JC Cowan","year":"2018","unstructured":"Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10-year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39:2975\u201383. https:\/\/doi.org\/10.1093\/eurheartj\/ehy411.","journal-title":"Eur Heart J"},{"key":"1625_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","volume":"194","author":"BA Steinberg","year":"2017","unstructured":"Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132\u201340. https:\/\/doi.org\/10.1016\/j.ahj.2017.08.011.","journal-title":"Am Heart J"},{"key":"1625_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003725","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725. https:\/\/doi.org\/10.1161\/JAHA.116.003725.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"1625_CR18","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2165\/11596820-000000000-00000","volume":"71","author":"J Watson","year":"2011","unstructured":"Watson J, Whiteside G, Perry C. Apixaban: first global approval. Drugs. 2011;71(15):2079\u201389. https:\/\/doi.org\/10.2165\/11596820-000000000-00000.","journal-title":"Drugs"},{"key":"1625_CR19","unstructured":"US Food and Drug Administration. Eliquis (apixaban) [prescribing information]. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf. Accessed 11 Jan 2026."},{"key":"1625_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","volume":"35","author":"M Colacci","year":"2020","unstructured":"Colacci M, Tseng EK, Sacks CA, Fralick M. Oral anticoagulant utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35:2505\u20137. https:\/\/doi.org\/10.1007\/s11606-020-05904-0.","journal-title":"J Gen Intern Med"},{"key":"1625_CR21","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","volume":"36","author":"JG Andrade","year":"2020","unstructured":"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol. 2020;36:1847\u2013948. https:\/\/doi.org\/10.1016\/j.cjca.2020.09.001.","journal-title":"Can J Cardiol"},{"key":"1625_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58:1265\u201379. https:\/\/doi.org\/10.1007\/s40262-019-00775-z.","journal-title":"Clin Pharmacokinet"},{"key":"1625_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bcp.12106","volume":"76","author":"C Frost","year":"2013","unstructured":"Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776\u201386. https:\/\/doi.org\/10.1111\/bcp.12106.","journal-title":"Br J Clin Pharmacol"},{"key":"1625_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/10760296211021158","volume":"27","author":"A Vu","year":"2021","unstructured":"Vu A, Qu TT, Ryu R, Nandkeolyar S, Jacobson A, Hong LT. Critical analysis of apixaban dose adjustment criteria. Clin Appl Thromb Hemost. 2021;27:107602962110211. https:\/\/doi.org\/10.1177\/10760296211021158.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1625_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/VHRM.S121944","volume":"13","author":"K Hurst","year":"2017","unstructured":"Hurst K, O\u2019Callaghan JM, Handa A. Quick reference guide to apixaban. Vasc Health Risk Manag. 2017;13:263\u20137. https:\/\/doi.org\/10.2147\/VHRM.S121944.","journal-title":"Vasc Health Risk Manag"},{"key":"1625_CR26","unstructured":"Agrawal A, Kerndt CC, Manna B. Apixaban. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507910\/. Accessed 22 Nov 2025."},{"key":"1625_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ijlh.12654","volume":"39","author":"C Wright","year":"2017","unstructured":"Wright C, Brown R, Cuker A. Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice. Int J Lab Hematol. 2017;39:31\u20136. https:\/\/doi.org\/10.1111\/ijlh.12654.","journal-title":"Int J Lab Hematol"},{"key":"1625_CR28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/S40265-014-0261-1","volume":"74","author":"H Bounameaux","year":"2014","unstructured":"Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014;74:1209\u201331. https:\/\/doi.org\/10.1007\/S40265-014-0261-1.","journal-title":"Drugs"},{"key":"1625_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/S40262-015-0342-7","volume":"55","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin\u00a0K antagonist oral anticoagulant that inhibits clotting factor\u00a0Xa. Clin Pharmacokinet. 2016;55:641\u201355. https:\/\/doi.org\/10.1007\/S40262-015-0342-7.","journal-title":"Clin Pharmacokinet"},{"key":"1625_CR30","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/EURHEARTJ\/EHU181","volume":"35","author":"GYH Lip","year":"2014","unstructured":"Lip GYH, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014;35:1844\u201355. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHU181.","journal-title":"Eur Heart J"},{"key":"1625_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/JCPH.1838","volume":"61","author":"V Ashton","year":"2021","unstructured":"Ashton V, Kerolus-Georgi S, Moore KT. The pharmacology, efficacy, and safety of rivaroxaban in renally impaired patient populations. J Clin Pharmacol. 2021;61:1010\u201326. https:\/\/doi.org\/10.1002\/JCPH.1838.","journal-title":"J Clin Pharmacol"},{"key":"1625_CR32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1389200218666170518165443","volume":"18","author":"T Kvasnicka","year":"2017","unstructured":"Kvasnicka T, Malikova I, Zenahlikova Z, Kettnerova K, Brzezkova R, Zima T, et al. Rivaroxaban: metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18:636\u201342. https:\/\/doi.org\/10.2174\/1389200218666170518165443.","journal-title":"Curr Drug Metab"},{"key":"1625_CR33","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/EURHEARTJ\/EHAE176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Kotecha D, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, et al. 2024 ESC Ggidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314\u2013414. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAE176.","journal-title":"Eur Heart J"},{"key":"1625_CR34","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024;149:E1-156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"key":"1625_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/PHAR.1884","volume":"37","author":"SE Conway","year":"2017","unstructured":"Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy. 2017;37:236\u201348. https:\/\/doi.org\/10.1002\/PHAR.1884.","journal-title":"Pharmacotherapy"},{"key":"1625_CR36","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/J.CHEST.2022.07.025","volume":"162","author":"JD Douketis","year":"2022","unstructured":"Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162:e207\u201343. https:\/\/doi.org\/10.1016\/J.CHEST.2022.07.025.","journal-title":"Chest"},{"key":"1625_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/JAMACARDIO.2017.0364","volume":"2","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non\u2013vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2:566\u201374. https:\/\/doi.org\/10.1001\/JAMACARDIO.2017.0364.","journal-title":"JAMA Cardiol"},{"key":"1625_CR38","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/BLOOD-2018-04-791541","volume":"132","author":"JM Connors","year":"2018","unstructured":"Connors JM. Testing and monitoring direct oral anticoagulants. Blood. 2018;132:2009\u201315. https:\/\/doi.org\/10.1182\/BLOOD-2018-04-791541.","journal-title":"Blood"},{"key":"1625_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/CPT.2927","volume":"114","author":"SY Lin","year":"2023","unstructured":"Lin SY, Tang SC, Kuo CH, Ho LT, Liu YB, Peng YF, et al. Impact of direct oral anticoagulant concentration on clinical outcomes in Asian patients with atrial fibrillation. Clin Pharmacol Ther. 2023;114:230\u20138. https:\/\/doi.org\/10.1002\/CPT.2927.","journal-title":"Clin Pharmacol Ther"},{"key":"1625_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/S-0041-1723770","volume":"47","author":"F Renon","year":"2021","unstructured":"Renon F, Rago A, Liccardo B, D\u2019Andrea A, Riegler L, Golino P, et al. Direct oral anticoagulants plasma levels measurement: clinical usefulness from trials and real-world data. Semin Thromb Hemost. 2021;47:150\u201360. https:\/\/doi.org\/10.1055\/S-0041-1723770.","journal-title":"Semin Thromb Hemost"},{"key":"1625_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/JCM13010216","volume":"13","author":"A Kessler","year":"2024","unstructured":"Kessler A, Kolben Y, Puris G, Ellis M, Alperin M, Simovich V, et al. Direct oral anticoagulants in special patient populations. J Clin Med. 2024;13:216. https:\/\/doi.org\/10.3390\/JCM13010216.","journal-title":"J Clin Med"},{"key":"1625_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/HEMATOLOGY.2019000027","volume":"2019","author":"R Sarode","year":"2019","unstructured":"Sarode R. Direct oral anticoagulant monitoring: what laboratory tests are available to guide us? Hematology. 2019;2019:194\u20137. https:\/\/doi.org\/10.1182\/HEMATOLOGY.2019000027.","journal-title":"Hematology"},{"key":"1625_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1517\/17425255.2016.1164692","volume":"12","author":"SS Zheng","year":"2016","unstructured":"Zheng SS, Chong JJH, Chong BH. Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis. Expert Opin Drug Metab Toxicol. 2016;12:575\u201380. https:\/\/doi.org\/10.1517\/17425255.2016.1164692.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1625_CR44","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/FJC.0000000000000870","volume":"76","author":"M Bernier","year":"2020","unstructured":"Bernier M, Lancrerot SL, Parassol N, Lavrut T, Viotti J, Rocher F, et al. Therapeutic drug monitoring of direct oral anticoagulants may increase their benefit-risk ratio. J Cardiovasc Pharmacol. 2020;76:472\u20137. https:\/\/doi.org\/10.1097\/FJC.0000000000000870.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"28","key":"1625_CR45","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehu046.","journal-title":"Eur Heart J"},{"key":"1625_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/S11239-018-1643-0","volume":"45","author":"A Rottenstreich","year":"2018","unstructured":"Rottenstreich A, Zacks N, Kleinstern G, Raccah BH, Roth B, Da\u2019as N, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis. 2018;45:543\u20139. https:\/\/doi.org\/10.1007\/S11239-018-1643-0.","journal-title":"J Thromb Thrombolysis"},{"key":"1625_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13584-019-0285-9","volume":"8","author":"A Perlman","year":"2019","unstructured":"Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Fisher Negev T, Hochberg-Klein S, et al. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019;8:19. https:\/\/doi.org\/10.1186\/s13584-019-0285-9.","journal-title":"Isr J Health Policy Res"},{"key":"1625_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/S11239-011-0591-8","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban\u2014an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183\u20137. https:\/\/doi.org\/10.1007\/S11239-011-0591-8.","journal-title":"J Thromb Thrombolysis"},{"key":"1625_CR49","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/S-0038-1627480","volume":"118","author":"RC Gosselin","year":"2018","unstructured":"Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118:437\u201350. https:\/\/doi.org\/10.1055\/S-0038-1627480.","journal-title":"Thromb Haemost"},{"key":"1625_CR50","unstructured":"For Healthcare Professionals. FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. Accessed 17 Jun 2025."},{"key":"1625_CR51","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1161\/CIR.0000000000000477","volume":"135","author":"AN Raval","year":"2017","unstructured":"Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting. Circulation. 2017;135:e604\u201333. https:\/\/doi.org\/10.1161\/CIR.0000000000000477.","journal-title":"Circulation"},{"key":"1625_CR52","volume-title":"Rowland and Tozer\u2019s clinical pharmacokinetics and pharmacodynamics concepts and applications","author":"H Derendorf","year":"2020","unstructured":"Derendorf H, Schmidt S. Rowland and Tozer\u2019s clinical pharmacokinetics and pharmacodynamics concepts and applications. 5th ed. Philadelphia: Wolters Kluwer; 2020. (Chapter 11).","edition":"5"},{"issue":"6","key":"1625_CR53","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s40120-025-00836-5","volume":"14","author":"KM Schubert","year":"2025","unstructured":"Schubert KM, Zelano J, Seiffge DJ, Brigo F, Trinka E, Mishra NK, et al. Safety and effectiveness of direct oral anticoagulants in combination with antiseizure medications: protocol for a systematic review and meta-analysis. Neurol Ther. 2025;14(6):2737\u201350. https:\/\/doi.org\/10.1007\/s40120-025-00836-5.","journal-title":"Neurol Ther"},{"key":"1625_CR54","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/J.JTHA.2025.06.031","volume":"23","author":"C Godino","year":"2025","unstructured":"Godino C, Mazza R, Gaspardone C, Minerva A, Sena R, Cozzani G, et al. Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events. J Thromb Haemost. 2025;23:3515\u201326. https:\/\/doi.org\/10.1016\/J.JTHA.2025.06.031.","journal-title":"J Thromb Haemost"},{"key":"1625_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1055\/A-2446-1348","volume":"125","author":"TAC De Vries","year":"2024","unstructured":"De Vries TAC, Mallick IU, Bhagirath VC, Eikelboom JW, Gomes C, Yi Q, et al. Usual on-therapy ranges of drug concentrations in patients with atrial fibrillation treated with direct oral anticoagulants: a systematic review and meta-analysis. Thromb Haemost. 2024;125:563\u201373. https:\/\/doi.org\/10.1055\/A-2446-1348.","journal-title":"Thromb Haemost"},{"key":"1625_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jth.13912","volume":"16","author":"J Douxfils","year":"2018","unstructured":"Douxfils J, Ageno W, Samama CM, Lessire S, ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16:209\u201319. https:\/\/doi.org\/10.1111\/jth.13912.","journal-title":"J Thromb Haemost"},{"key":"1625_CR57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/HEMATOLOGY.2024000666","volume":"2024","author":"S Mithoowani","year":"2024","unstructured":"Mithoowani S, Siegal D. DOACs: role of anti-Xa and drug level monitoring. Hematology. 2024;2024:178\u201385. https:\/\/doi.org\/10.1182\/HEMATOLOGY.2024000666.","journal-title":"Hematology"},{"key":"1625_CR58","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/JAMACARDIO.2022.1292","volume":"7","author":"B Bikdeli","year":"2022","unstructured":"Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, et al. Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review. JAMA Cardiol. 2022;7:747\u201359. https:\/\/doi.org\/10.1001\/JAMACARDIO.2022.1292.","journal-title":"JAMA Cardiol"},{"key":"1625_CR59","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/BJH.13810","volume":"172","author":"BJ Dale","year":"2016","unstructured":"Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172:315\u201336. https:\/\/doi.org\/10.1111\/BJH.13810.","journal-title":"Br J Haematol"},{"key":"1625_CR60","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","volume":"64","author":"A Cuker","year":"2014","unstructured":"Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2014.05.065.","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01625-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01625-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01625-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:25:46Z","timestamp":1774963546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01625-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01625-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Meir Bialer received in the last 5 years consultancy fees from Angelini Pharma, Clexio Therapeutics, Guidepoint, Meditec (Sam On), NeuroSense Therapeutics, Pharma2B, Selene Therapeutics, Shackelford Pharma, and Xenon Pharmaceuticals. Mordechai Muszkat received honoraria from Roche and a research grant from the Pfizer Independent Global Medical Grant. Rachel Goldstein, Khaled Sandouka, Lana Zighan, and Shaul Yaari have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets analyzed during the study are not publicly available because of institutional and patient privacy regulations, but are available from the corresponding author upon reasonable request and with permission from Hadassah Medical Center.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RG, KS, LZ, MM, and MB conceived and designed the study, collected and analyzed the data, and drafted the manuscript. RG, KS, and MM contributed to data analysis and interpretation. SY, MM, and MB provided supervision and critical revision of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}